Endothelial progenitor cells are clonal and exhibit the JAK2 V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms

Blood

Volumn 117, Issue 9, 2011, Pages 2700-2707

  Teofili, Luciana ^a   Martini, Maurizio ^a   Iachininoto, Maria Grazia ^a   Capodimonti, Sara ^a   Nuzzolo, Eugenia Rosa ^a   Torti, Lorenza ^a   Cenci, Tonia ^a   Larocca, Luigi Maria ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CD146 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; HYDROXYUREA; INTERFERON; JANUS KINASE 2; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA METHYLATION; ENDOTHELIAL PROGENITOR CELL; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GRANULOCYTE; HUMAN; HUMAN CELL; LUNG EMBOLISM; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STROKE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

EID: 79953071111     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-297598     Document Type: Article

References (36)

1. Yoshimoto M, Yoder MC. Developmental biology: birth of the blood cell. Nature. 2009;459(7250): 1131-1135.
2. Pelosi E, Valtieri M, Coppola S, et al. Identification of the hemangioblast in postnatal life. Blood. 2002;100(9):3203-3208. (Pubitemid 35217068)
3. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313-320. (Pubitemid 46878103)
4. Santilli F, Romano M, Recchiuti A, et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin- treated polycythemia vera patients. Blood. 2008;112(4):1085-1090.
5. Oppliger Leibundgut E, Horn MP, Brunold C, et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica. 2006;91(11):1465-1472. (Pubitemid 44736112)
6. Piaggio G, Rosti V, Corselli M, et al. Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood. 2009; 114(14):3127-3130.
7. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-1809. (Pubitemid 46348173)
8. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246-5249.
9. Sozer S, Ishii T, Fiel MI, et al. Human CD34 cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis. 2009;43(3):304-312.
10. Jost E, do O N, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21(3):505-510.
11. Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008; 123(7):1586-1592.
12. Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2008; 141(4):504-511. (Pubitemid 351550557)
13. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41(2 Suppl 3):1-5. (Pubitemid 38657103)
14. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380. (Pubitemid 44232040)
15. Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32-38.
16. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006; 108(10):3548-3555.
17. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
18. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593-600. (Pubitemid 36204953)
19. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752-2760. (Pubitemid 39434958)
20. Teofili L, Iachininoto MG, Capodimonti S, et al. Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. 2010; 24(16):2443-2450).
21. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
22. Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood. 2007;110(1):354-359. (Pubitemid 47026854)
23. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25(9):1048-1052.
24. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468. (Pubitemid 46193073)
25. Teofili L, Cenci T, Martini M, et al. The mutant JAK2 allele burden in children with essential thrombocythemia. Br J Haematol. 2009;145(3):430-432.
26. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981-2987. (Pubitemid 40814192)
27. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112(8):3026-3035.
28. Fang B, Zheng C, Liao L, et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood. 2005;105(7):2733-2740. (Pubitemid 40446263)
29. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood. 2006;107(6):2531-2535. (Pubitemid 43345578)
30. Streubel B, Chott A, Huber D, et al. Lymphomaspecific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351(3):250-259. (Pubitemid 38916042)
31. Wang L, O'Leary H, Fortney J, Gibson LF. Ph/ VE-cadherin identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood. 2007;110(9):3334-3344. (Pubitemid 350106327)
32. Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000;355(9216):1688-1691. (Pubitemid 30248482)
33. Wu J, Huang L, Huang M, et al. Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia. Exp Hematol. 2009;37(1):87-91.
34. Marchetti M, Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb. 2008;36(3-4):148-159.
35. Banes-Berceli AK, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB. Angiotensin II and endothelin-1augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol. 2007;293(2):1291-1299.
36. Manea SA, Manea A, Heltianu C. Inhibition of JAK/STAT signaling pathway prevents high-glucose- induced increase in endothelin-1 synthesis in human endothelial cells. Cell Tissue Res. 2010;340(1):71-79.